Varian Medical Systems, Nashville, TN 37203, USA.
Tennessee Oncology, Nashville, TN 37203, USA.
Future Oncol. 2020 Mar;16(7):263-268. doi: 10.2217/fon-2019-0835. Epub 2020 Jan 27.
The NK-1 receptor antagonist HTX-019 (CINVANTI [aprepitant injectable emulsion]) was approved for preventing chemotherapy-induced nausea and vomiting based on bioequivalence studies in healthy volunteers. The objective of this study was to evaluate HTX-019 safety in cancer patients. This retrospective analysis evaluated the safety of HTX-019 130 mg 30-min intravenous infusion, as part of a three-drug antiemetic regimen. No treatment-emergent adverse events (TEAEs) were deemed related to HTX-019. During treatment cycles, three of 100 patients developed five reversible TEAEs: dyspnea, hot flash, pain, nausea and visual disturbance. Between cycles, six patients had TEAEs of dizziness (three patients), infusion-site events (two patients) and headache (two patients). HTX-019 is safe in cancer patients receiving chemotherapy.
NK-1 受体拮抗剂 HTX-019（CINVANTI[阿瑞匹坦注射液]）已基于健康志愿者的生物等效性研究获得批准，可用于预防化疗引起的恶心和呕吐。本研究旨在评估 HTX-019 在癌症患者中的安全性。这项回顾性分析评估了 HTX-019 130mg 静脉输注 30 分钟作为三药止吐方案的一部分的安全性。无治疗出现的不良事件（TEAEs）被认为与 HTX-019 相关。在治疗周期中，100 名患者中有 3 人出现了 5 种可逆的 TEAEs：呼吸困难、热潮红、疼痛、恶心和视力障碍。在治疗周期之间，6 名患者出现了 TEAEs，包括头晕（3 名患者）、输注部位事件（2 名患者）和头痛（2 名患者）。HTX-019 在接受化疗的癌症患者中是安全的。
